KOL Investor Event - SOL-GEL TECHNOLOGIES LTD

Financial Performance:

• No specific revenue, profit, or cash flow figures were disclosed for the current fiscal period as the company is pre-revenue with a focus on drug development.
• Management indicated a "very high" contribution margin and profitability potential upon launch due to the drug's high price point relative to the low number of required sales reps (approx. 20 FTEs for ~200 centers of excellence).
• The company plans to self-fund and retain the majority of commercial economics rather than licensing the asset to a larger partner.
• Capital raised includes significant additional investment from management to support the current Phase 3 trial.

Guidance and Future Outlook:

• Clinical Milestones: Topline results for the current Phase 3 study expected "next month"; NDA submission targeted for April; Approval anticipated by Q2 2027 (leveraging Orphan Drug and Breakthrough Therapy designations); US Commercial launch scheduled for early 2028.
• Market Size: Conservative US peak sales model assumes 11,000 diagnosed patients (excluding those without significant BCCs and pediatric patients initially), leading to ~600,000 eligible patients after demographic adjustments; projected peak penetration of 4,000 patients (65% of the treated population).
• Product Expansion: Long-term goals include expanding indications to non-Gorlin high-frequency BCC, reducing the size of existing tumors (neoadjuvant therapy for surgery), and extending treatment to other body areas (neck, scalp, hands, legs) and potentially pediatrics once safety data is mature.
• IP: Strong intellectual property protection expected until at least 2045.

Business Segments and Product Lines:

• Core Asset: SGT-610 (patidegib gel), a topical hedgehog pathway inhibitor.
• Mechanism: Blocks the Hedgehog signaling pathway (specifically targeting the Smoothened protein) to prevent new Basal Cell Carcinomas (BCCs) and reduce tumor volume.
• Study Design Improvements: The company overhauled the Phase 3 study design based on post-hoc analysis of prior Pelopharm data, implementing:
  • Mandatory PTCH1 mutation status (enriching for responders).
  • Requirement of ≥3 facial BCCs (vs. 10 in the initial study) to capture efficacy in less advanced disease.
  • Use of dermoscopes and central photography review boards to reduce false positives/negatives ("zigzag effects").
  • Reduced patient dropouts to ~10% (down from historical rates).
• New Applications: Investigating use for Odontogenic Keratocysts (OKCs) by impregnating gauze with the drug, and as a neoadjuvant agent to shrink tumors prior to surgery.

Market and Competitive Landscape:

• Patient Needs: Addresses a "desperate need" in the Gorlin Syndrome community; 94% of surveyed patients prefer a preventive treatment with no major side effects over current options.
• Current Alternatives:
  • Surgery (Mohs/Excision): Gold standard but causes scarring, disfigurement, surgical fatigue, and loss of time; inefficient for patients with hundreds of tumors.
  • Oral Hedgehog Inhibitors (e.g., Vismodegib, Sonidegib): Highly effective but suffer from severe tolerability issues (muscle cramps, taste changes, hair loss, teratogenicity), leading to high discontinuation rates (approx. 54% on continuous dosing).
  • Topical Chemotherapy/Immunotherapy (5-FU, Imiquimod): Only effective for superficial lesions and cause significant irritation/scarring.
• Competitive Advantage: SGT-610 offers similar efficacy to oral inhibitors but with a topical route, minimizing systemic side effects and offering a "prevention" mechanism (interception) rather than just treatment.
• Commercialization: Unique "boutique" market (approx. 600 eligible US patients at launch) allows for an independent US launch by a small team, avoiding the complexity of global pricing controls that may necessitate partners in Europe.

Risks and Challenges:

• Study Power & Efficacy: Concerns regarding the placebo response in patients with low BCC counts; the company argues that efficacy is constant across BCC counts but placebo stability masks drug benefit in low-burden patients.
• Regulatory Uncertainty: Need to convince the FDA that enrichment strategies (PTCH1 mutation, ≥3 BCCs) in the Phase 3 trial will translate to broader labeling eligibility (e.g., lower BCC counts).
• Compliance: High adherence is critical for a chronic daily topical treatment; management plans to invest heavily in patient support programs to prevent treatment fatigue.
• Safety in Pediatrics: Currently restricted to adults; pediatric expansion depends on accumulating safety data regarding growth plate impact.
• Market Access: Pricing strategy must balance high-value topicals with the reality of global price controls to prevent negative spillover into the US market.

Management Commentary and Tone:

• Tone: Highly confident, optimistic, and patient-centric. Management expressed strong conviction that the drug will be "life-changing."
• Confidence: Management emphasized that they have corrected all flaws in the previous Pelopharm study design, citing a "compelling" data set and alignment with FDA recommendations to identify sensitive patient populations.
• Strategy: Firm stance on independent US commercialization to retain economics, citing the focused target audience and high efficacy/safety profile as enablers for a lean commercial team.

Analyst Questions and Answers:

• Phase 3 Powering: Management confirmed the study (113 enrolled, 102 completed) is sufficiently powered to detect a 40% reduction in new BCCs, even if the 50% reduction seen in post-hoc analysis is not met.
• Genetic Subgroups: Clarified that ~80% of patients have PTCH1 mutations (highly responsive), ~5% have SUFU mutations (potentially less responsive/resistant due to downstream mechanisms), and ~10-15% have unknown mutations.
• Labeling Expectations: Management and KOLs expect the FDA to approve a label broader than the trial inclusion criteria (e.g., allowing treatment for patients with <10 BCCs), as physicians can exercise clinical judgment and the drug's mechanism is proven in the "interception" model.
• Adoption Speed: KOLs and patient advocates anticipate rapid adoption due to the lack of viable alternatives and the "if you build it, they will come" dynamic in the rare disease community.
• Placebo Dynamics: Analysts questioned if higher baseline BCC counts correlate with higher placebo response (new tumor growth). KOLs agreed that higher baseline burden likely correlates with higher disease acceleration, reinforcing the need for early treatment initiation.

Other Key Points:

• Patient Advocacy: Strong involvement of the Gorlin Syndrome Alliance (GSA); the CEO highlighted the emotional impact of the disease, noting that patients view life as a constant battle against new cancers.
• Scientific Validation: Dr. Ervin Epstein (co-founder of the pathway discovery and former consultant to Pelopharm) provided extensive background on the Hedgehog pathway, noting that oral inhibitors work because of this mechanism, validating the topical approach.
• Future Vision: The ultimate goal is to prevent new tumors entirely ("interception"), potentially rendering Mohs surgery unnecessary for the majority of new lesions in this population.
• Operational Efficiency: The new study design minimized "zigzag effects" (variability in lesion counting) through strict use of dermoscopy and central review, resulting in high data quality.